Smoking and vaping; cessation; treatment mechanisms; ADHD; psychophysiology; cognition and motivation/emotion
Buffalo NY, 14260-4110
Phone: (716) 645-0192
A controlled evaluation of abstinence-induced withdrawal and motivation to vape/smoke among daily ENDS users vs. cigarette smokers. Withdrawal is considered a major feature of nicotine/tobacco addiction and a key challenge to quitting smoking and/or electronic nicotine delivery systems (ENDS). However, little is known about nicotine withdrawal in ENDS users or its role in driving product use. This project systematically and comprehensively characterizes withdrawal among daily vapers compared to daily smokers, filling gaps in our understanding of ENDS dependence/abuse liability and contributing to the development of therapies.
Automatic detection of vaping rate and patterning in the lab and the natural environment using Flexible, Robust Instrumentation of Electronic Nicotine Delivery Systems (FRIENDS). Our ability to accurately characterize and non-obtrusively track ENDS puff behavior is quite limited. To overcome this barrier, this research uses a novel Flexible Robust Instrumentation of ENDS (FRIENDS) monitor to assess puff behavior in the lab and natural environment. We aim to advance our understanding of ENDS use behavior, make available to the field a validated, inexpensive, and accurate method for future studies, and guide the development of improved self-report assessments.
EVarQuit: Extinguishing cigarette smoking via extended pre-quit varenicline. This project aims to improve cessation rates obtained with varenicline by a simple but theory-based manipulation: increasing the duration of pre-quit varenicline treatment from 1 to 4 weeks. Positive results of this trial can be readily applied to reduce the public health burden of smoking, and the mechanistic data collected in the study will refine theory and guide treatment development.
We collaborate on other funded projects, with our lab focusing on cognitive performance and clinical psychophysiology: